The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues

• Autorzy: Bucan V , Reimers K. , Choi C. Y. , Eddy M.-T. , Vogt P.M.
• Języki publikacji: EN

Abstrakty

EN

Lifeguard (LFG) is an anti-apoptotic protein that inhibits Fas-mediated death in tumour cells. However, the molecular function of human LFG in the carcinogenesis of human breast cells is uncertain. We studied the expression and function of endogenous LFG in four breast cancer cell lines (MCF-7, MDA-MB-231, T-47D and HS 578T), a human breast epithelial cell line (HS 578Bst), and in healthy and cancerous breast tissues. Molecular (Western blot and RT-PCR) and immunohistochemical techniques were used to investigate the LFG expression. To investigate the breast cancer cell proliferation in the presence of Fas, we performed fluorescent cell viability assays. The possible association of Fas with LFG was analyzed by immunofluorescence microscopy. In this paper, we provide convincing evidence that LFG is overexpressed in several human breast cancer cell lines. More importantly, we found that the LFG expression correlates with high tumour grades in primary breast tumours. Finally, we demonstrated that Fas sensitivity is reduced in breast cancer cell lines expressing LFG. Our results indicated that LFG is strongly expressed in breast cancer epithelial cells. Moreover, the overexpression of LFG correlated with tumour grade and reduced Fas sensitivity. Our findings support the idea that LFG may have a role in the downregulation of apoptosis in breast cancer cells.

Słowa kluczowe

EN

apoptosis; antiapoptotic protein; lifeguard; cancer; breast cancer; cancer cell; cancer tissue; carcinogenesis; epithelial cell line

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2010
• Tom: 15
• Numer: 2
• Opis fizyczny: p.296-310,fig.,ref.

Twórcy

autor

Bucan V

• Medical School of Hannover, Podbielskistrasse 380, D-30659 Hannover, Germany

autor

Reimers K.

autor

Choi C. Y.

autor

Eddy M.-T.

autor

Vogt P.M.

Bibliografia

• 1. Reed, J.C. Mechanisms of apoptosis. Am. J. Pathol. 157 (2000) 1415-1430.
• 2. Sjostrom, J. and Bergh, J. How apoptosis is regulated, and what goes wrong in cancer. BMJ 322 (2001) 1538-1539.
• 3. Boise, L.H., Gonzalez-Garcia, M., Postema, C.E., Ding, L., Lindsten, T., Turka, L.A., Mao, X., Nunez, G. and Thompson, C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993) 597-608.
• 4. Boyd, J.M., Gallo, G.J., Elangovan, B., Houghton, A.B., Malstrom, S., Avery, B.J., Ebb, R.G., Subramanian, T., Chittenden, T. and Lutz, R.J. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11 (1995) 1921-1928.
• 5. Oltvai, Z.N., Milliman, C.L. and Korsmeyer, S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619.
• 6. Yang, E., Zha, J., Jockel, J., Boise, L.H., Thompson, C.B. and Korsmeyer, S.J. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 80 (1995) 285-291.
• 7. Certo, M., Del, G.M., Nishino, M., We, I.G., Korsmeyer, S., Armstrong, S.A. and Letai, A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006) 351-365.
• 8. Uren, R.T., Dewson, G., Chen, L., Coyne, S.C., Huang, D.C., Adams, J.M. and Kluck, R.M. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J. Cell. Biol. 177 (2007) 277-287.
• 9. Willis, S.N., Fletche,r J.I., Kaufmann, T., van Delft, M.F., Chen, L., Czabotar, P.E., Ierino, H., Lee, E.F., Fairlie, W.D., Bouillet, P., Strasser, A., Kluck, R.N., Adams, S.M. and Huang, D.C. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007) 856-859.
• 10. Yethon, J.A., Epand, R.F., Leber, B., Epand, R.M. and Andrews, D.W. Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. J. Biol. Chem. 278 (2003) 48935-48941.
• 11. Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D., Schuler, M. and Green, D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014.
• 12. Orrenius, S. Apoptosis: molecular mechanisms and implications for human disease. J. Intern. Med. 237 (1995) 529-536.
• 13. Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462.
• 14. Reed, J.C. and Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood 106 (2005) 408-418.
• 15. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., Joseph, M.K., Kitada, S., Korsmeyer, S.J., Kunzer, A.R., Letai, A., Li, C., Mitten, M.J., Nettesheim, D.G., Ng, S., Nimmer, P.M., O'Connor, J.M., Oleksijew, A., Petros, A.M., Reed, J.C., Shen, W., Tahir, S.K., Thompson, C.B., Tomaselli, K.J., Wang, B., Wendt, M.D., Zhang, H., Fesik, S.W. and Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681.
• 16. Haldar, S., Negrini, M., Monne, M., Sabbioni, S. and Croce, C.M. Downregulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54 (1994) 2095-2097.
• 17. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. p53 mutations in human cancers. Science 253 (1991) 49-53.
• 18. Ikegaki, N., Katsumata, M., Minna, J. and Tsujimoto, Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. 54 (1994) 6-8.
• 19. Liang, X.H., Mungal, S., Ayscue, A., Meissner, J.D., Wodnicki, P., Hockenbery, D., Lockett, S. and Herman, B. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J. Cell Biochem. 57 (1995) 509-521.
• 20. McDonnell, T.J., Troncoso, P., Brisbay, S.M., Logothetis, C., Chung, L.W., Hsieh, J.T., Tu, S.M. and Campbell, M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res. 52 (1992) 6940-6944.
• 21. Yang, Q., Sakurai, T., Yoshimura, G., Suzuma, T., Umemura, T., Nakamura, M., Nakamura, Y., Mori, I. and Kakudo, K. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol. Rep. 10 (2003) 121-125.
• 22. Yang, Q.F., Sakurai, T., Yoshimura, G., Shan, L., Suzuma, T., Tamaki, T., Umemura, T., Kokawa, Y., Nakamura, Y., Nakamura, M., Tang, W., Utsunomiya, H., Mori, I. and Kakudo, K. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res. Treat. 61 (2000) 211-216.
• 23. Fernandez, M., Segura, M.F., Sole, C., Colino, A., Comella, J.X. and Cena, V. Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. J. Neurochem. 103 (2007) 190-203.
• 24. Somia, N.V., Schmitt, M.J., Vetter, D.E., Van Antwerp, D., Heinemann, S.F. and Verma, I.M. LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc. Natl. Acad. Sci. USA 96 (1999) 12667-12672.
• 25. Jean, J.C., Oakes, S.M. and Joyce-Brady, M. The Bax inhibitor-1 gene is differentially regulated in adult testis and developing lung by two alternative TATA-less promoters. Genomics 57 (1999) 201-208.
• 26. Xu, Q. and Reed, J.C. Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol. Cell 1 (1998) 337-346.
• 27. Reimers, K., Choi, C.Y., Mau-Thek, E. and Vogt, P.M. Sequence analysis shows that Lifeguard belongs to a new evolutionarily conserved cytoprotective family. Int. J. Mol. Med. 18 (2006) 729-734.
• 28. Schweitzer, B., Taylor, V., Welcher, A.A., McClelland, M. and Suter, U. Neural membrane protein 35 (NMP35): a novel member of a gene family which is highly expressed in the adult nervous system. Mol. Cell Neurosci. 11 (1998) 260-273.
• 29. Schweitzer, B., Suter, U. and Taylor, V. Neural membrane protein 35/Lifeguard is localized at postsynaptic sites and in dendrites. Brain Res. Mol. Brain Res. 107 (2002) 47-56.
• 30. Plati, J., Bucur, O. and Khosravi-Far, R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J. Cell Biochem. 104 (2008) 1124-1149.
• 31. Melet, A., Song, K., Bucur, O., Jagani, Z., Grassian, A.R. and Khosravi-Far, R. Apoptotic pathways in tumor progression and therapy. Adv. Exp. Med. Biol. 615 (2008) 47-79.
• 32. Sturm, I., Papadopoulos, S., Hillebrand, T., Benter, T., Luck, H.J., Wolff, G., Dörken, B. and Daniel, P.T. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int. J. Cancer 87 (2000) 517-521.
• 33. Soufla, G., Baritaki, S., Sifakis, S., Zafiropoulos, A. and Spandidos, D.A. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix. Int. J. Biol. Markers 20 (2005) 18-27.
• 34. Bargou, R.C., Daniel, P.T., Mapara, M.Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H.D. and Dörken, B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 60 (1995) 854-859.
• 35. Haldar, S., Negrini, M., Monne, M., Sabbioni, S. and Croce, C.M. Downregulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54 (1994) 2095-2097.
• 36. Leek, R.D., Kaklamanis, L., Pezzella, F., Gatter, K.C. and Harris, A.L. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptorpositive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer 69 (1994) 135-139.
• 37. Stark, A.M., Pfannenschmidt, S., Tscheslog, H., Maass, N., Rosel, F., Mehdorn, H.M. and Held-Feindt, J. Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation. Neurol. Res. 28 (2006) 787-793.
• 38. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V.M., Niskanen, E., Nordling, S. and Reed, J.C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55 (1995) 4471-4478.
• 39. Grzmil, M., Thelen, P., Hemmerlein, B., Schweyer, S., Voigt, S., Mury, D. and Burfeind, P. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am. J. Pathol. 163 (2003) 543-552.
• 40. Grzmil, M., Kaulfuss, S., Thelen, P., Hemmerlein, B., Schweyer, S., Obenauer, S., Kang, T.W. and Burfeind, P. Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells. J. Pathol. 208 (2006) 340-349.
• 41. Tanaka, R., Ishiyama, T., Uchihara, T., Inadome, Y., Iijima, T., Morishita, Y., Kano, J., Goya, T. and Noguchi, M. Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma. Cancer 106 (2006) 648-653.
• 42. Villalva, C., Trempat, P., Greenland, C., Thomas, C., Girard, J.P., Moebius, F., Delsol, G. and Brousset, P. Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma. Br. J. Haematol. 188 (2002) 791-798.
• 43. Reimers, K., Choi, C.Y., Bucan, V. and Vogt, P.M. The Bax Inhibitor-1 (BI-1) family in apoptosis and tumorigenesis. Curr. Mol. Med. 8 (2008) 148-156.
• 44. Esseghir, S., Reis-Filho, J.S., Kennedy, A., James, M., O'Hare, M.J., Jeffery, R., Poulsom, R. and Isacke, C.M. Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J. Pathol. 210 (2006) 420-430.
• 45. Nagata, S. and Golstein, P. The Fas death factor. Science 267 (1995) 1449-1456.
• 46. Hengartner, M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776.
• 47. Landowski, T.H., Gleason-Guzman, M.C. and Dalton, W.S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89 (1997) 1854-1861.
• 48. Toillon, R.A., Descamps, S., Adriaenssens, E., Ricort, J.M., Bernard, D., Boilly, B. and Le Bourhis, X. Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling. Exp. Cell Res. 275 (2002) 31-43.